Hybrigenics improves inecalcitol synthesis
New Hybrigenics patent application for high-yield inecalcitol production
The originality of the chemical structure of inecalcitol resides in the so-called "14-epimer" conformation of the vitamin D backbone. The lack of hypercalcemic effect and, as a consequence, the excellent tolerance of high doses of inecalcitol, can be explained in part by this unique structural configuration. During the scale-up of the chemical synthesis of inecalcitol, special conditions were found to improve the effectiveness of "14-epimerization". This new and inventive chemical process is now protected by a worldwide patent application procedure.
"We originally licensed the exclusive patent rights for inecalcitol itself and for part of its synthesis. Last year we filed a patent on the therapeutic use of high doses of inecalcitol, and now we have moved to protect 14-epimerization," said Rémi Delansorne, Hybrigenics' CEO. "Our strategy is to optimize all components of inecalcitol development and to build several intellectual property barriers around it."
Most read news
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.